RRM2 and neoplasm: Furthermore, targeting RRM2 could complement antiviral therapies in HBV/HCV-related HCC by concurrently suppressing viral replication and tumor progression (Kitab and Tsukiyama-Kohara 2023a; Wu et al. 2024).